Influx Healthtech Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 28 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹689 Cr
Influx Healthtech targets a minimum growth of 25% to 30% in FY '27, with ambitions to surpass this range, potentially reaching 35% to 40% based on past achievements. The company expects a minimum growth of 25% to 30% in revenue for FY '27, with potential to exceed up to 35%-40% based on past performance.
From Influx Healthtech Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹292
Market Cap
₹689 Cr
P/E Ratio
33.5
Revenue Rank
Margin Rank
How does Influx Healthtech Ltd rank in Pharmaceuticals & Biotechnology?
Compare Influx Healthtech Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 2- →Influx Healthtech targets a minimum growth of 25% to 30% in FY '27, with ambitions to surpass this range, potentially reaching 35% to 40% based on past achievements.
- →The company anticipates steady capacity utilization growth, with new plants expected to be operational around August, contributing approximately INR 40-50 crores in H2 FY '27.
- →The veterinary segment and pet care market are expected to grow significantly, with capacity increasing from 150 kg/hour to around 1000 kg/hour (an 8x increase), gradually improving margins.
- →Export revenues currently contribute around 15-20%, with an expected annual increase of 5-7% in export quantum.
- →Growth will be driven by both scaling existing clients and acquiring new clients, with the top 50-100 clients steadily expanding.
- →Long-term revenue targets aim for INR 450-500 crores facilitated by planned capacity expansion (2.5x current capacity).
📈 Profitability & Margins
Rank 3- →The company expects a minimum growth of 25% to 30% in revenue for FY '27, with potential to exceed up to 35%-40% based on past performance.
- →Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) margins are targeted around 20% to 22%.
- →Profit After Tax (PAT) margins are expected to be maintained around 14%.
- →New facility commissioning in July-August 2026 is expected to contribute approximately INR 40-50 crores to revenue in H2 FY '27.
- →Gradual capacity utilization increases are anticipated; the new facility brings 2.5x installed capacity growth.
- →The company plans controlled, steady growth avoiding large upfront investments without secured clients.
- →Export revenue is expected to grow 5%-7% year-on-year, increasing its contribution beyond the current 15%-20%.
- →Employee cost increases reflect investments in capability building to support growth.
- →Overall, sustainable and steady improvement in profits and EPS aligned with capacity expansion and operational efficiencies.
🏗️ Capital Expenditure Plans
Yes- →INR 13.84 crores of IPO proceeds allocated for capex utilized as of March 31, 2026.
- →Board approved reallocation of INR 10 crores from veterinary, home care, and cosmetic divisions to expand nutraceutical CDMO facility.
- →New facility (~75,000 sq. ft.) commissioning expected by July/August 2026, capacity to be 2.5x existing, targeting INR 450-500 crores revenue in a few years.
- →Installed a new granulation line with ~480 kg/day capacity (24,000 bottles/day).
- →Protein/snack bar segment growing strongly; pet food extrusion line ordered, capacity increasing from 100-150 kg/hr to 1000 kg/hr.
- →Beverage segment building a canning facility and carbonated line; includes Tetra pack line booked.
- →Investment in innovative packaging machinery (e.g., for cosmetics) imported.
- →No current plans for debt; growth capex funded through internal accruals and IPO proceeds.
- →Focus on steady, strategic capacity expansion matching customer demand.
💰 Fundraising & Capital Structure
No- →Currently, Influx Healthtech has sufficient funds from internal accruals and IPO proceeds to operate and expand.
- →No plans to raise new debt at present; the company does not intend to take on debt right now.
- →For the next 2-3 years, the company expects to fund growth capex primarily from internal accruals and IPO proceeds.
- →Management indicated no expectation of equity dilution or additional fundraising during this period.
- →Any additional expansion or capacity increase will be planned within existing financial resources unless future needs arise.
📋 Order Book & Pipeline
Yes- →The company does not have long-term contracts typical in the industry, with some clients providing projections for 3 months to 1 year (e.g., Octavius has given a 1-year plan, Novus a 3-month projection).
- →Existing clients are growing steadily and contributing to the order book; the top 50-100 clients remain largely the same.
- →The new facility, equipped with more automated lines, is expected to serve larger clients, while the current facility will cater to medium and small clients.
- →Capacity utilization is expected to build slowly and steadily; filling the new capacity will take time and is not expected immediately.
- →The company anticipates regular growth of 25-30% year-on-year, inclusive of contributions from the new facility.
- →The order pipeline looks healthy with new clients like Nykaa, Khandelwal Labs, and Aristo joining.
- →The management is confident about meeting utilization and maintaining growth momentum.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Influx Healthtech Ltd Q4 FY26 results?
Influx Healthtech targets a minimum growth of 25% to 30% in FY '27, with ambitions to surpass this range, potentially reaching 35% to 40% based on past achievements. The company expects a minimum growth of 25% to 30% in revenue for FY '27, with potential to exceed up to 35%-40% based on past performance.
What is Influx Healthtech Ltd share price analysis?
Influx Healthtech Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 33.5 with a market cap of ₹689 Cr. Investors should review the full earnings analysis for detailed insights.
Is Influx Healthtech Ltd planning capital expenditure?
INR 13.84 crores of IPO proceeds allocated for capex utilized as of March 31, 2026. - Board approved reallocation of INR 10 crores from veterinary, home care, and cosmetic divisions to expand nutraceutical CDMO facility. - New facility (~75,000 sq.
Keep Influx Healthtech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.